Onychomycosis Treatment Market Positioned for Growth with Rising Adoption of Laser Therapies

The global onychomycosis treatment market is set for consistent expansion, driven by rising fungal infection prevalence, increased awareness of nail health, and a growing emphasis on advanced therapeutics. According to recent industry estimates, the market is expected to be valued at US$ 4.1 billion in 2025, and is projected to reach US$ 5.8 billion by 2032, reflecting a CAGR of 5.1% during the forecast period. With onychomycosis comprising nearly half of all nail disorders globally, stakeholders across pharmaceuticals, healthcare, and dermatology are preparing to address a sustained rise in treatment demand.

Rising Burden of Nail Fungal Infections Boosts Market Momentum

Onychomycosis, a fungal infection affecting fingernails and toenails, is increasingly prevalent due to aging populations, lifestyle changes, and higher incidences of conditions like diabetes and peripheral vascular disease—both of which heighten susceptibility to fungal infections. The rise of immunocompromised patient groups, including cancer and HIV patients, has also contributed to higher infection rates.

In addition, public awareness of the importance of nail health is growing, partly influenced by expanding cosmetic services and nail-care markets. As more consumers seek professional care for nail abnormalities, early detection and diagnosis rates have improved, thereby increasing the uptake of treatment solutions.

The growth of specialized dermatology clinics and availability of both prescription and over-the-counter antifungal therapies further support the expanding market base.

Market Forecast and Key Trends

The period from 2025 to 2032 is expected to witness notable shifts across the onychomycosis treatment landscape. Several emerging trends are poised to shape market dynamics:

Rising Adoption of Combination Therapies

While traditional treatment relied heavily on oral drugs or topical therapies alone, combination approaches are gaining ground due to higher efficacy rates. Pairing oral antifungals with topical solutions or laser therapy is becoming increasingly common in clinical settings.

Advancements in Laser and Photodynamic Therapy

Laser devices designed for fungal nail treatment have evolved significantly, offering faster, non-invasive alternatives with minimal side effects. Although still expensive, these technologies are projected to gain wider adoption as patient demand for cosmetic and non-pharmaceutical solutions rises.

Shift Toward Safer, High-Efficacy Topical Formulations

Concerns surrounding the side effects of oral antifungal drugs, particularly liver toxicity, have intensified interest in newer, safer topical solutions. Pharmaceutical companies are investing in formulations with enhanced nail penetration and quicker action.

Strengthening Distribution Through Online Pharmacies

E-commerce and telemedicine are playing an increasingly important role in dermatological care. Sales of topical antifungals through online pharmacies are growing rapidly, aided by user-friendly platforms and discreet treatment options for patients hesitant to seek in-person care.

Read More: https://www.persistencemarketresearch.com/market-research/onychomycosis-treatment-market.asp

Segmental Insights

By Treatment

The onychomycosis treatment market is segmented into drugs, topicals, laser & photodynamic therapy, and others.

Drugs

Oral antifungal drugs continue to command a significant share of the market due to their high clinical efficacy and ability to treat severe infections. However, safety concerns are pushing innovation toward more tolerable options.

Topicals

This segment is experiencing accelerated growth, supported by continuous R&D in nail-penetration technology and increased preference for non-systemic treatments. Topicals are particularly popular for mild to moderate onychomycosis.

Laser & Photodynamic Therapy

Laser devices are gaining steam in dermatology clinics and specialty centers. Though costly, their appeal lies in non-invasive treatment without systemic side effects.

Others

This category includes alternative therapies and emerging technologies currently in development.

By Disease Type

The market is categorized into distal subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis, and others.

Distal Subungual Onychomycosis

Representing the most common form of the disease, this segment accounts for a dominant share of treatment demand. Its high prevalence across age groups ensures sustained market contribution.

Proximal Subungual Onychomycosis

Often associated with immunosuppressed individuals, this segment is expected to see rising treatment volumes as screening improves.

White Superficial Onychomycosis

Though less common, it is usually easier to treat, fueling adoption of topical therapies.

Others

Includes rarer fungal nail disorders, contributing marginally to overall market revenue.

By End-User

Market end-users include hospitals, specialty clinics, ambulatory surgery centers (ASCs), and others.

Hospitals

Hospitals represent a key end-user segment, primarily due to their role in managing severe or systemic fungal infections requiring prescription medications.

Specialty Clinics

Dermatology and podiatry clinics are among the fastest-growing sectors, driven by demand for cosmetic procedures and laser therapies.

Ambulatory Surgery Centers

ASCs are increasingly adopting laser and photodynamic devices, enhancing their presence in the market.

Others

Smaller clinics, home-care users, and retail pharmacy consumers contribute to this category.

Regional Outlook

North America

North America is projected to maintain a strong market position, driven by high healthcare expenditure, awareness levels, and availability of advanced laser therapies. The U.S. alone accounts for a substantial share due to its aging population and widespread healthcare access.

Europe

Europe follows closely, supported by favorable reimbursement policies and rising dermatological consultations. Countries like Germany, France, and the UK exhibit strong demand for both pharmaceutical and device-based treatments.

East Asia

East Asia is emerging as a high-growth region, propelled by expanding healthcare infrastructure and increasing adoption of cosmetic dermatology. Japan and South Korea see notable uptake of laser treatments.

South Asia & Oceania

The region is witnessing improving awareness and rising fungal infection rates. India remains a significant market, driven by population growth and higher prevalence of diabetes.

Latin America

Countries like Brazil and Mexico are experiencing moderate growth, supported by rising healthcare spending and greater accessibility of generic antifungal medications.

Middle East & Africa

Although still developing, MEA is gradually enhancing its dermatology care capabilities. Urban centers are leading growth, with gradually improving diagnosis rates.

Competitive Landscape

The onychomycosis treatment market features a mix of global pharmaceutical giants, dermatology specialists, and emerging biotech firms. Key players include Pfizer Inc., Dr. Reddy's Laboratories, Novartis AG, Galderma, GSK, Johnson & Johnson, Kaken Pharmaceuticals, Merz Pharma, Moberg Pharma, Bausch Health Companies Inc., Taro Pharmaceuticals, Eisai Co., Ltd., and DM Pharma.

These companies are focusing on product innovation, strategic collaborations, and expanding distribution networks. Many are targeting improved drug formulations, novel delivery methods, and advanced device technologies to gain market share.

Mergers and acquisitions remain prevalent as firms look to strengthen dermatology product portfolios, while ongoing clinical trials signal advancements in treatment options and formulations.

Growth Factors and Challenges

Growth Factors

• Increasing global prevalence of fungal nail infections

• Expanding geriatric and diabetic populations

• Advancements in topical and laser-based therapies

• Growing awareness of cosmetic nail health

• Rising availability of OTC and online treatment options

Challenges

• High recurrence rate of onychomycosis

• Long treatment durations reducing patient compliance

• Adverse effects associated with oral antifungal drugs

• High cost of laser treatments limiting widespread adoption

• Limited diagnostic facilities in developing regions

Future Opportunities and Revenue Pockets

The next decade holds significant opportunities in the onychomycosis market. Demand for novel topical formulations with enhanced penetration capabilities is expected to surge. The increasing acceptance of laser and photodynamic therapy opens avenues for medical device expansion. Moreover, biotech companies exploring new antifungal molecules and nanotechnology-based delivery systems may unlock strong revenue streams.

Growth is also anticipated from emerging economies, where expanding healthcare access and rising aesthetic awareness provide fertile ground for market penetration.

Conclusion

As the global burden of fungal nail infections continues to rise, the onychomycosis treatment market is set for sustained expansion. Supported by technological advancements, evolving therapeutic options, and strengthened healthcare infrastructure, the industry is poised to reach US$ 5.8 billion by 2032. Companies investing in innovation, patient-centric solutions, and region-specific strategies are expected to capture the most value in the coming years.